10 results about "Mesenchymal Progenitor Cell" patented technology

Provided herein are methods and related compositions for enhancing or enhanced partial reprogramming of target cells in a subject in need thereof (e.g., a human subject suffering from or at risk of a disease), the method comprising administering a plurality of mesenchymal lineage progenitor or stem cells (MLPSCs), exosomes derived therefrom, or conditioned culture media derived therefrom to a subject that expresses or will express one or more reprogramming factors in a population of target cells, whereby a plurality of the target cells in the subject become partially reprogrammed, but not fully reprogrammed.

The present disclosure relates to heterogeneous cell compositions derived from canine or feline uterine tissue and methods of producing and use thereof. In some aspects, the heterogeneous cell compositions comprise a mixture of mesenchymal progenitor cells and epithelial progenitor cells. In some aspects, the heterogeneous cell compositions are used as an autologous or allogeneic treatment for the treatment of diseases such as chronic kidney disease, atopic dermatitis, immune mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune mediated polyarthritis or wounds in canines and felines.

Disclosed are methods of in situ genomic modification of cells (e.g., stem cells, tissue stem cells, muscle stem cells, Sca-1+ mesenchymal progenitor cells in skeletal muscle, CD140a+ dermal mesenchymal cells) using sequence-targeting nucleases delivered via a virus (e.g., an AAV).

Disclosed are methods of in situ genomic modification of cells (e.g., stem cells, tissue stem cells, muscle stem cells, Sca-1+ mesenchymal progenitor cells in skeletal muscle, CD140a+ dermal mesenchymal cells) using sequence-targeting nucleases delivered via a virus (e.g., an AAV).

Disclosed herein are methods for generating dopaminergic neurons and organoids comprising thereof. Particularly, the disclosure relates to methods for generating dopaminergic neurons by differentiating stem or precursor cells into Achaete-scute family bHLH transcription factor 1 (Ascl1)-driven mesenchymal progenitor cells and then terminally differentiating the Ascl1-driven mesenchymal progenitor cells into dopaminergic neurons alone or alongside astrocyte and hematopoietic precursor cells.

Described herein are neonatal cardiac mesenchymal progenitor cells, an nMPC secretome, or an nMPC exosome for treating Amyotrophic Lateral Sclerosis (ALS) in a subject. One or more doses of neonatal cardiac mesenchymal progenitor cells, an nMPC secretome, an nMPC exosome, an nMPC total secretome, or a combination thereof can be administered to the subject. Neonatal cardiac mesenchymal progenitor cells can be allogeneic. The subject may also be administered one or more combination therapies.

To solve the problem in which: although a variety of therapeutic agents have been used for treating pain and / or inflammation, including chronic pain and / or inflammation, the treatment is often still ineffective; in particular, back pain is often poorly managed or controlled even by chronic administration of such agents; this may be due to the loss of potency of the agent and / or the development of side effects associated with chronic treatment with the agent.SOLUTION: A method of treating lower back pain in a subject in need thereof comprises administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs), where the lower back pain is associated with an intervertebral disc that has an intervertebral disc height that is not substantially reduced compared to that of an adjacent healthy intervertebral disc in the subject.SELECTED DRAWING: None

The present disclosure relates to potency assays for cell therapy products. To provide a potency assay of a cell population comprising mesenchymal progenitor or stem cells.SOLUTION: The present invention relates to a method of measuring the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor or stem cells based on the levels of TGF-9 they release during culture. The invention also relates to an isolated population of mesenchymal lineage precursor or stem cells selected on the basis of the level of TGF-9 levels that the cells release in culture. The invention further relates to treating a subject suffering from degenerative disc disease by administering a cell population so selected.SELECTED DRAWING: None

To develop a ready-to-use ex vivo expanded allogeneic mesenchymal progenitor or stem cell (MLPSC) product having improved immunosuppressive activity.SOLUTION: The present disclosure relates to cell therapy products comprising mesenchymal lineage precursor or stem cells and potency assays for these products. The present disclosure also relates to a method for treating an immune or inflammatory disease, for treating or preventing graft versus host disease (GVHD) or one or more symptoms associated with GVHD by administering mesenchymal lineage precursor or stem cells.SELECTED DRAWING: None

To provide off-the-shelf ex vivo expanded allogeneic mesenchymal lineage precursor or stem cell (MLPSC) product which has improved immunosuppressive activity.SOLUTION: The present disclosure relates to cellular therapy products comprising mesenchymal lineage precursor or stem cells and potency assay for these products. The present disclosure also relates to methods for treatment of immune or inflammatory disorders, and treatment or prevention of graft versus host disease (GVHD), or one or more symptoms associated with GVHD, by administration of mesenchymal lineage precursor or stem cells.SELECTED DRAWING: None